{
  "drug_name": "Ceftobiprole medocaril",
  "tradename": "Zevtera",
  "usage_and_dosing": {
    "general": [
      "Ceftobiprole medocaril is an advanced generation parenteral cephalosporin with activity against some gram positive and gram negative bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). It is a prodrug that is rapidly converted to ceftobiprole presumably by plasma esterases.",
      "In vitro spectrum of activity is similar to Ceftaroline.",
      "Approved by the US FDA in April 2024 for these indications:",
      "Adults with S. aureus bacteremia, including those with right-sided IE, caused by MSSA and MRSA.",
      "Adults with acute bacterial skin and skin structure infections (ABSSSI) caused by MSSA, MRSA, S. pyogenes, and K. pneumoniae.",
      "Adult and pediatric patients with CAP caused by MSSA, S. pneumoniae, H. influenzae, H. parainfluenzae, E. coli, and K. pneumoniae.",
      "Not approved in the US for ventilator-associated pneumonia (VAP).",
      "Approved in the EU, Switzerland and Canada for community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP), but not VAP.",
      "An alternative antibiotic for drug resistant genotypes.",
      "Susceptible to hydrolysis by ESBLs and AmpC cephalosporinases.",
      "Non-inferior to daptomycin based on overall treatment success in patients with complicated S. aureus bacteremia: N Engl J Med 2023; 389:1390"
    ],
    "adult_dose": {
      "s_aureus_bacteremia": "667 mg IV q6h on day 1-8, then 667 mg IV q8h from day 9 on (up to 42 days).",
      "absssi_cap": "667 mg IV q8h x5-14 days.",
      "equivalence": "667 mg of ceftobiprole medocaril is equivalent to 500 mg of ceftobiprole.",
      "infusion": "Infuse doses over 2 hours. Compatible with D5W or NS. Do not co-administer with calcium-containing solutions."
    },
    "pediatric_dose": {
        "cap_egfr_ge_50": {
            "age_3_mon_to_lt_12_yrs": "20 mg/kg (max 667 mg) q8h x7-14 days",
            "age_12_yrs_to_lt_18_yrs": "13.3 mg/kg (max 667 mg) q8h x7-14 days"
        },
        "cap_egfr_lt_50": {
            "age_2_yrs_to_lt_6_yrs_by_egfr": {
                "30_to_lt_50": "13.3 mg/kg q12h (max 667 mg)",
                "15_to_lt_30": "13.3 mg/kg q24h (max 333 mg)"
            },
            "age_6_yrs_to_lt_12_yrs_by_egfr": {
                "30_to_lt_50": "10 mg/kg (max 667 mg) q12h",
                "15_to_lt_30": "10 mg/kg (max 333 mg) q24h"
            },
            "age_12_yrs_to_lt_18_yrs_by_egfr": {
                "30_to_lt_50": "10 mg/kg (max 667 mg) q12h",
                "15_to_lt_30": "10 mg/kg (max 333 mg) q12h"
            },
            "lt_15": "No data"
        },
        "max_day": "-"
    }
  },
  "renal_adjustment": {
    "half_life_normal": "3.3",
    "half_life_esrd": "21",
    "dose_renal_function_normal": "667 mg IV q8h",
    "crcl_or_egfr": {
        "gt_150": "667 mg q6h",
        "ge_50_to_150": "No dosage adjustment",
        "30_to_lt_50": "SAB: 667 mg q8h days 1-8, then q12h. ABSSSI, CAP: 667 mg q12h",
        "15_to_lt_30": "SAB: 333 mg q8h days 1-8, then q12h. ABSSSI, CAP: 333 mg q12h",
        "lt_15": "333 mg q24h"
    },
    "hemodialysis": "333 mg q24h (AD on dialysis days)",
    "capd": "No data",
    "crrt": "No data",
    "sled": "No data"
  },
  "hepatic_adjustment": {
    "mild_impairment_child_pugh_a": "No dosage adjustment",
    "moderate_impairment_child_pugh_b": "No dosage adjustment",
    "severe_impairment_child_pugh_c": "No dosage adjustment"
  },
  "other_adjustment": {
      "ecmo": "No dose adjustment likely required. See Table for more information."
  },
  "adverse_effects": {
      "most_common": [
          "Nausea, vomiting, diarrhea",
          "Hypersensitivity (urticaria, rash)",
          "Infusion site reactions",
          "Dysgeusia"
      ],
      "less_common": [
          "Thrombocytopenia, agranulocytosis",
          "Anaphylaxis",
          "C. difficile colitis",
          "Agitation (anxiety, panic attack, nightmares), seizures"
      ]
  },
  "pregnancy_risk": {
    "fda_risk_category": "No evidence of toxicity in humans; evidence of minor maternal adverse effects in animals (↓ body weight, ↓ appetite).",
    "lactation": "No data, but adverse effects not expected. Monitor infant for GI toxicity.",
    "footnote": "Capital letter = Old FDA risk category; Text = New FDA risk category"
  },
  "antimicrobial_spectrum": {
    "preferred": [],
    "alternative": []
  },
  "pharmacology": {
    "pk_pd_index": "T>MIC",
    "preparations": "Injection",
    "food_recommendation": null,
    "oral_absorption_percent": null,
    "tmax_hr": null,
    "peak_serum_conc_ug_ml": "33.0 (667 mg IV q8h, SS)",
    "peak_urine_conc_ug_ml": "No data",
    "protein_binding_percent": "16",
    "volume_of_distribution_vd_l_vss": "18 L (Vss)",
    "avg_serum_half_life_hr": "3.3",
    "elimination": "Renal",
    "bile_penetration_percent": "No data",
    "csf_blood_percent": "12% (conc 1.2 µg/mL) (Heliyon 2024;10:e27285)",
    "therapeutic_levels_in_csf": "Possibly",
    "auc_ug_hr_ml": "102 (667 mg IV q8h, 0-8h)"
  },
  "enzyme_transporter_mediated_interactions": {
      "cyp450s_substrate": [],
      "transporters_substrate": [],
      "ugts_substrate": [],
      "cyp450s_inhibited": [],
      "transporters_inhibited": ["OATP1B1/3"],
      "ugts_inhibited": [],
      "cyp450s_induced": [],
      "transporters_induced": [],
      "ugts_induced": [],
      "impact_on_serum_drug_concentrations": "↑"
  },
  "major_drug_interactions": [
    "No clinically relevant drug interactions known"
  ]
}
